DM4 is primarily utilized in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. It functions as a potent cytotoxic agent that is linked to monoclonal antibodies, which specifically bind to antigens on cancer cells. Once the ADC is internalized by the cancer cell, DM4 is released, disrupting microtubule function and leading to cell death. This approach minimizes damage to healthy tissues, making it a valuable component in precision medicine for treating various cancers, including breast, lung, and lymphoma. Its high potency and targeted delivery enhance the efficacy of cancer treatments while reducing systemic toxicity.